## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is intended to assist in the understanding and assessing the trends and significant changes in the Company's results of operations and financial condition. Historical results may not be indicative of future performance. This discussion includes forward-looking statements that reflect the Company's plans, estimates and beliefs. Such statements involve risks and uncertainties. The Company's actual results may differ materially from those contemplated by these forward-looking statements as a result of various factors, including those set forth in "Risk Factors" in Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2020 (the "2020 Form 10-K"), and "Cautionary Statement Regarding Forward-Looking Statements" set forth below.

This MD&A should be read in conjunction with the Company's unaudited condensed consolidated financial statements for the three month period ended September 30, 2021 and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this "Quarterly Report" or "Form 10-Q") and the 2020 Form 10-K. Financial information presented in this MD&A is presented in thousands of U.S. dollars, unless otherwise indicated.

## **Cautionary Statement Regarding Forward Looking-Statements**

This Quarterly Report of the Company contains statements that include forward-looking information and are forward-looking statements within the meaning of applicable Canadian and United States securities legislation ("forward-looking statements"), including the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. All statements, other than statements of historical fact, included herein are forward-looking statements, including, for greater certainty, the on-going implications of the novel coronavirus ("COVID-19") and statements regarding the proposed transaction with Canopy Growth Corporation ("Canopy Growth"), including the anticipated benefits and likelihood of completion thereof.

Generally, forward-looking statements may be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. There can be no assurance that such forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking statements. Forward-looking statements reflect Acreage's current beliefs and are based on information currently available to Acreage and on assumptions Acreage believes are reasonable. Forward-looking statements is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Acreage to be materially different from those expressed or implied by such forward-looking statements. Such risks and other factors may include, but are not limited to:

- the future implications to the business, financial results and performance of the Company arising, directly or indirectly, from COVID-19;
- the anticipated benefits of the Amended Arrangement;
- the occurrence or waiver of the Triggering Event (as described in Note 13 of the unaudited condensed consolidated financial statements);
- the ability of Acreage to satisfy the conditions to closing of the Acquisition;
- the ability of Acreage to meets its performance targets and financial thresholds agreed upon with Canopy Growth as part of the Amended Arrangement, including those that are conditions to closing the Acquisition;
- the likelihood of the Triggering Event being satisfied or waived by the outside date;
- the likelihood of Canopy Growth completing the acquisition of the Fixed Shares and/or Floating Shares;
- risks related to the ability to financing Acreage's business and fund its obligations;
- other expectations and assumptions concerning the transactions contemplated between Canopy Growth and Acreage;

- the available funds of Acreage and the anticipated use of such funds;
- · the availability of financing opportunities for Acreage and the risks associated with the completion thereof;
- regulatory and licensing risks;
- changes in general economic, business and political conditions, including changes in the financial and stock markets;
- risks related to infectious diseases, including the impacts of the novel coronavirus;
- legal and regulatory risks inherent in the cannabis industry;
- · risks associated with economic conditions, dependence on management and currency risk;
- risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks;
- risks relating to anti-money laundering laws and regulation;
- other governmental and environmental regulation;
- public opinion and perception of the cannabis industry;
- risks related to contracts with third-party service providers;
- risks related to the enforceability of contracts and lack of access to U.S. bankruptcy protections;
- reliance on the expertise and judgment of senior management of Acreage;
- risks related to proprietary intellectual property and potential infringement by third parties;
- the concentrated voting control of Acreage's founder and the unpredictability caused by Acreage's capital structure;
- risks relating to the management of growth;
- increasing competition in the industry;
- risks inherent in an agricultural business;
- risks relating to energy costs;
- risks associated to cannabis products manufactured for human consumption including potential product recalls;
- · reliance on key inputs, suppliers and skilled labor;
- cybersecurity risks;
- ability and constraints on marketing products;
- fraudulent activity by employees, contractors and consultants;
- tax and insurance related risks;
- risks related to the economy generally;
- risk of litigation;
- conflicts of interest;
- risks relating to certain remedies being limited and the difficulty of enforcement judgments and effecting service outside of Canada;

- risks related to future acquisitions or dispositions;
- · sales by existing shareholders; and
- limited research and data relating to cannabis.

A description of additional assumptions used to develop such forward-looking statements and a description of additional risk factors that may cause actual results to differ materially from forward-looking statements can be found in Part I, Item 1A of the Company's Annual Report on Form 10-K, under the heading "Risk Factors", dated March 25, 2021, as filed with the Securities and Exchange Commission. Although Acreage has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking statements contained in this Form 10-Q are expressly qualified by this cautionary statement. The forward-looking statements contained in this Form 10-Q represent the expectations of Acreage as of the date of this Form 10-Q and, accordingly, are subject to change after such date. However, Acreage expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Management's discussion and analysis of financial condition and results of operations is intended to help provide an understanding of the Company's financial condition, changes in financial condition and results of operations. This discussion is organized as follows:

- *Overview*—This section provides a general description of the Company's businesses, its strategic objectives, as well as developments that occurred during the three and nine months ended September 30, 2021 and 2020 that the Company believes are important in understanding its results of operations and financial condition or to disclose known trends.
- Results of Operations—This section provides an analysis of the Company's results of operations for the three and nine
  months ended September 30, 2021 and 2020. This analysis is presented on a consolidated basis. In addition, a brief
  description is provided of significant transactions and events that impact the comparability of the results being analyzed.
- Liquidity and Capital Resources—This section provides an analysis of the Company's cash flows for the nine months ended September 30, 2021 and 2020, as well as a discussion on the Company's outstanding debt and commitments that existed as of September 30, 2021. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to fund the Company's future commitments and obligations, as well as a discussion of other financing arrangements.

#### Overview

Acreage, a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S, was continued into the Province of British Columbia under the *Business Corporations Act* (British Columbia). Acreage Fixed Shares and Floating Shares (as such terms are defined at Note 13 of the unaudited condensed consolidated financial statements) are each listed on the Canadian Securities Exchange under the symbols "ACRG.A.U" and "ACRG.B.U", respectively, and are quoted on the OTCQX® Best Market by OTC Markets Group under the symbols "ACRHF" and "ACRDF", respectively and on the Open Market of the Frankfurt Stock Exchange under the symbols "0VZ1" and "0VZ2", respectively. Acreage operates through its consolidated subsidiary High Street Capital Partners, LLC ("HSCP"), a Delaware limited liability company. HSCP, which does business as "Acreage Holdings", was formed on April 29, 2014. The Company became an indirect parent of HSCP on November 14, 2018 in connection with a reverse takeover ("RTO") transaction. The Company's operations include (i) cultivating cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing high-quality, effective and dosable cannabis products to consumers. The Company appeals to medical and adult-use customers through brand strategies intended to build trust and loyalty.

As of September 30, 2021, Acreage owned and operated a total of 22 dispensaries - five dispensaries in Oregon (three in Portland, one in Eugene and one in Springfield), four in New York (Buffalo, Farmingdale, Middletown and Queens), three in New Jersey (Atlantic City, Egg Harbor and Williamstown), three in Connecticut (Bethel, South Windsor and Uncasville), two in Massachusetts (Worcester and Shrewsbury), two in Illinois (Chicago and Rolling Meadows), and three in Maine (Gardiner, Portland and South Portland). As of September 30, 2021, Acreage owned and operated a total of 6 cultivation and processing facilities in Oakland, California, Sinking Spring, Pennsylvania, Sterling, Massachusetts, Syracuse, New York, Freeport, Illinois, and Egg Harbor, New Jersey. Acreage also collected management and consulting services revenues, substantially all in Maine and New Hampshire.

## Strategic Priorities

The Company believes its refocused strategy is the key to continued improvements in its financial results and shareholder value. The Company remains focused on three key strategic objectives - driving profitability, strengthening the balance sheet, and accelerating growth in its core markets.

*Driving Profitability*: The Company's focus on improving operational and financial results has resulted in generally improving profitability. Management continues to diligently control costs, improve operational efficiencies, and accelerate organic growth in its core markets to continue to report improved profitability going forward.

Strengthening the Balance Sheet: Strengthening the balance sheet is key to both providing the Company with the necessary capital to achieve its operational plans and building shareholder confidence. The Company has worked to ensure that sufficient capital has been available when needed. Going forward, the Company will monitor the capital markets and utilize opportunities to access both debt or equity when it is necessary and advantageous to do so.

Accelerating Growth in Core Markets: Through prior acquisitions and capital expenditures, management believes Acreage is well positioned for future success in several key markets as regulations regarding the use of cannabis continue to evolve. The Company will continue to focus its growth on its core markets where it can take advantage of and expand on the presence already established.

# Highlights from the three months ended September 30, 2021:

- The Company achieved total consolidated revenue growth of 52% as compared with the three months ended September 30, 2020. On a sequential basis, the Company achieved total consolidated revenue growth of 9% compared with the three months ended June 30, 2021.
- Adjusted EBITDA for the three months ended September 30, 2021 was \$6.5 million compared to an adjusted EBITDA loss of \$6.9 million in the same period in 2020. This marks the third consecutive quarter of positive adjusted EBITDA for the company and validates management's refocused strategic plan.
- Hurricane Ida caused extensive damage to the Company's cultivation facility located in Sewell, New Jersey, which was
  nearing the completion of its construction. As a result, the Company wrote off the value of the capital assets at the
  Sewell, New Jersey locations and incurred a one-time charge, net of expected insurance proceeds of \$2.3 million.
- The Company entered into a definitive agreement and management services agreements to sell, upon regulatory approval, four retail dispensaries in Oregon for total consideration of \$6.5 million,
- Subsequent to September 30, 2021, the Company completed the acquisition of Greenleaf Apothecaries, LLC, Greenleaf
  Therapeutics, LLC and Greenleaf Gardens, LLC (together "Greenleaf), an operator of cultivation, processing and retail
  facilities in Ohio,

## Additional highlights from the nine months ended September 30, 2021:

- The Company achieved total consolidated revenue growth of 57% as compared with the nine months ended September 30, 2020.
- Adjusted EBITDA for the nine months ended September 30, 2021 was \$16.2 million compared to an adjusted EBITDA loss of \$26.0 million in the same period in 2020.
- The Company opened its third New Jersey based The Botanist dispensary in Williamstown, New Jersey.
- The Company completed the acquisition of 100% of CWG Botanicals, Inc. ("CWG"), an adult-use cannabis cultivation and processing operations in the state of California.
- The Company completed the sale of its operations in Florida for aggregate proceeds of \$60.0 million, which is consistent with its overall strategy to focus on its core states.
- The Company agreed to sell its dispensary in Powell, Oregon and its cultivation and processing facility in Medford, Oregon.
- The Company utilized the proceeds from the sale of Acreage Florida and its restricted cash to strengthen its balance sheet. During the nine months ended September 30, 2021, the Company reduced its external debt by \$46.3 million.
- The Company reached an agreement with Medterra CBD, LLC, one of the largest CBD companies in the industry, that.will allow Acreage Holdings to tap into Medterra's innovation pipeline, high-quality CBD, and significant ecommerce platform for nationwide distribution of a suite of branded CBD products.

## Operational and Regulation Overview

The Company believes its operations are in material compliance with all applicable state and local laws, regulations and licensing requirements in the states in which it operates. However, cannabis is illegal under U.S. federal law. Substantially all of the Company's revenue is derived from U.S. cannabis operations. For information about risks related to U.S. cannabis operations, please refer to Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2020.

### Results of Operations for Three Months Ended September 30, 2021 and 2020

The following table presents selected financial data derived from the unaudited condensed consolidated financial statements of the Company for the three and nine months ended September 30, 2021 and 2020. The selected financial information set out below may not be indicative of the Company's future performance.

<b>Summary Results of Operations</b>			Better/(Worse)					
in thousands, except per share amounts	Three Months Ended September 30,		2021 v	s. 2020		iths Ended	2021 vs. 2020	
	2021	2020	\$	%	2021	2020	\$	%
Revenues, net	\$ 48,151	\$ 31,742	\$ 16,409	52 %	\$130,762	\$ 83,039	\$ 47,723	57 %
Operating loss	(6,496)	(38,580)	32,084	83 %	(11,444)	(329,197)	317,753	97 %
Net loss attributable to Acreage	(12,297)	(40,548)	28,251	70 %	(22,657)	(249,694)	227,037	91 %
Basic and diluted loss per share attributable to Acreage	\$ (0.11)	\$ (0.39)	\$ 0.28	72 %	\$ (0.21)	\$ (2.54)	\$ 2.33	92 %

## Revenues, Cost of goods sold and Gross margin

The Company derives its revenues from sales of cannabis and cannabis-infused products through retail dispensary, wholesale and manufacturing and cultivation businesses, as well as from management or consulting fees from entities for whom the Company provides management or consulting services.

Gross profit is revenue less cost of goods sold. Cost of goods sold includes costs directly attributable to inventory sold such as direct material, labor, and overhead, including depreciation. Such costs are further affected by various state regulations that limit the sourcing and procurement of cannabis and cannabis-related products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes.

			Better/	(Worse)			Better/(	Worse)
in thousands		Three Months Ended September 30,		2021 vs. 2020		ths Ended iber 30,	2021 vs. 2020	
	2021	2020	\$	%	2021	2020	\$	%
Retail revenue, net	\$ 30,794	\$ 23,914	\$ 6,880	29 %	\$ 85,038	\$ 61,362	\$ 23,676	39 %
Wholesale revenue, net	17,077	7,798	9,279	119 %	42,634	21,513	21,121	98 %
Other revenue, net	280	30	250	833 %	3,090	164	2,926	n/m
Total revenues, net	\$ 48,151	\$ 31,742	\$ 16,409	52 %	\$ 130,762	\$ 83,039	\$ 47,723	57 %
Cost of goods sold, retail	(16,279)	(14,134)	(2,145)	(15)%	(43,412)	(37,004)	(6,408)	(17)%
Cost of goods sold, wholesale	(8,069)	(4,133)	(3,936)	(95)%	(19,049)	(11,395)	(7,654)	(67)%
Total cost of goods sold	\$ (24,348)	\$ (18,267)	\$ (6,081)	(33)%	\$ (62,461)	\$ (48,399)	\$(14,062)	(29)%
Gross profit	\$ 23,803	\$ 13,475	\$ 10,328	77 %	\$ 68,301	\$ 34,640	\$ 33,661	97 %
Gross margin	49 %	43 %		6 %	52 %	42 %		10 %

Total revenues increased by \$16,409 or 52% for the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020. On a comparative basis, total revenue increased by \$5,961 due to the acquisitions of (i) certain Maine operations and (ii) CWG in April 2021 and was offset by decreases of \$542 due to the divestitures/closures of (i) Maryland Medicinal Research & Caring, LLC and Acreage North Dakota, LLC in May 2020, (ii) Form Factory in March 2020 and iii) Acreage Florida in April 2021. Additionally, revenue for the three months ended September 30, 2021 for the Company's operations in Oregon, which are considered non-core and are being held for sale, decreased by \$1,035 as compared to the corresponding period in fiscal 2020. Excluding these acquisitions and divestitures/closures and the impact of revenue declines in the Company's Oregon operations, total revenue increased by \$12,025 or 42% for the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020.

Retail revenue increased by \$6,880 or 29% for the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020. Excluding the impact of acquisitions and divestitures/closures, retail revenue increased by \$3,746 for the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020. The remaining increase in retail revenue was primarily driven by increased demand and production across various states, and new store openings and was partially offset by retail revenue declines of \$911 in non core states (Oregon).

Wholesale revenue increased by 119% for the three months ended September 30, 2021, as compared to the corresponding periods of fiscal 2020. The increased wholesale revenue was primarily due to increased capacity, coupled with maturing operations at the Company's Pennsylvania, Massachusetts, and Illinois cultivation facilities. This resulted in higher yields and product mix in each of the respective markets. Additionally, wholesale revenue for the three months ended September 30, 2021 included \$2,189 from CWG which was acquired in April 2021.

On a year-to-date basis, total revenues for the nine months ended September 30, 2021, increased by \$47,723 or 57% as compared to the corresponding period of fiscal 2020. On a comparative basis, total revenues increased by \$18,651 due to the acquisitions of (i) CCF in June 2020, (ii) certain Maine operations and (iii) CWG in May 2021 and was offset by decreases of \$1,629 due to the divestitures/closures of (i) Maryland Medicinal Research & Caring, LLC and Acreage North Dakota, LLC in May 2020, (ii) Form Factory in March 2020 and (iii) Acreage Florida in April 2021. Additionally, total revenues for the nine months ended September 30, 2021 for the Company's operations in Oregon, which are considered non-core and are being held for sale, decreased by \$2,575 as compared to the corresponding period in fiscal 2020. Excluding these acquisitions and divestitures/closures and the impact of total revenue declines in the Company's Oregon operations, total revenue increased by \$33,275 or 46% for the nine months ended September 30, 2021, as compared to the corresponding period of fiscal 2020. Finally, total revenue for the nine months ended September 30, 2021 included \$2,500 of management fees in New Hampshire, a portion of which related to prior fiscal periods.

While total revenues increased 52%, total costs of goods sold only increased 33% for the three months ended September 30, 2021, as compared with the corresponding period of fiscal 2020.

Retail cost of goods sold increased 15% for the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020, and below the 29% increase in retail revenue. The lower rate of growth for retail cost of goods sold was due to the increased vertical integration of the Company's operations. A greater portion of the product sold at the Company's retail dispensaries is sourced internally from the Company's cultivation and processing operations. Cost of goods sold for this internally produced product does not contain the wholesale margin that would be paid if the Company had to source that same product from external vendors.

Wholesale cost of goods sold increased 95% for the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020, and below the 119% increase in wholesale revenue. While wholesale cost of goods sold increased due to the volume increase associated with the wholesale revenue growth, the rate of growth was lower as a result of production efficiencies being achieved. In addition, wholesale cost of goods sold for the comparative period were driven by the initial set up costs and consequential expansion impact of various cultivation facilities that was not as significant in the current period.

On a year-to-date basis, while total revenues increased 57%, total costs of goods sold only increased 29% for the nine months ended September 30, 2021, as compared with the corresponding period of fiscal 2020. The reasons for the increases in costs of goods sold and for the lower rate of growth of costs of goods sold compared to the revenue growth, for the nine months ended September 30, 2021, are consistent with the reasons for the three months ended September 30, 2021.

Gross margin for the three months ended September 30, 2021 was 49.4%, compared to 42.5% for the three months ended September 30, 2020. Gross margin for the nine months ended September 30, 2021 was 52.2%, compared to 41.7% for the nine months ended September 30, 2020. The increase in gross margin was driven by the factors discussed above.

#### Revenue by geography

While the Company operates under one operating segment, the production and sale of cannabis products, the below revenue breakout by geography is included as management believes it provides relevant and useful information to investors.

Revenue by region	Better/(Worse)						Better/	(Worse)
in thousands		Three Months Ended September 30,			Nine Months Ended September 30,			
	2021	2020	\$	%	2021	2020	\$	%
New England	\$ 19,892	\$ 12,598	\$ 7,294	58 %	\$ 56,070	\$ 36,520	\$ 19,550	54 %
Mid-Atlantic	14,695	11,217	3,478	31 %	43,474	25,622	17,852	70 %
Midwest	10,012	4,810	5,202	108 %	22,333	12,050	10,283	85 %
West	3,552	2,700	852	32 %	8,264	8,082	182	2 %
South		417	(417)	n/m	621	776	(155)	(20)
Total revenues, net	\$ 48,151	\$ 31,742	\$ 16,409	52 %	\$130,762	\$ 83,039	\$ 47,723	57 %

n/m - Not Meaningful

#### Total operating expenses

Total operating expenses consist primarily of compensation expense at the Company's corporate offices as well as operating subsidiaries, impairment losses, professional fees, which includes, but is not limited to, legal and accounting services, depreciation and other general and administrative expenses.

Operating expenses	Better/(Worse)						Better/(V	Worse)
in thousands	Three Months Ended September 30,		2021 vs. 2020			nths Ended nber 30,	2021 vs. 2020	
	2021	2020	\$	%	2021	2020	\$	%
General and administrative	\$ 8,466	\$ 14,819	\$ 6,353	43 %	\$ 23,067	\$ 40,237	\$ 17,170	43 %
Compensation expense	10,699	8,306	(2,393)	(29)%	32,236	30,740	(1,496)	(5)%
Equity-based compensation expense	4,168	10,445	6,277	60 %	17,191	65,369	48,178	74 %
Marketing	583	46	(537)	n/m	992	1,514	522	34 %
Impairments, net	2,339	_	(2,339)	n/m	3,157	187,775	184,618	98
Loss on notes receivable	_	_	_	n/m	1,726	8,161	6,435	79
Write down (recovery) of assets held-for-sale	_	2,893	2,893	n/m	(8,616)	11,003	19,619	n/m
Legal settlements, net	_	14,150	14,150	n/m	322	14,150	13,828	98 %
Depreciation and amortization	4,044	1,396	(2,648)	(190)%	9,670	4,888	(4,782)	(98)%
Total operating expenses	\$ 30,299	\$ 52,055	\$ 21,756	42 %	\$ 79,745	\$363,837	\$284,092	78 %

#### n/m - Not Meaningful

Total operating expenses for the three months ended September 30, 2021 were \$30,299, a decrease of \$21,756 or 42% from the corresponding period of fiscal 2020. The primary drivers of the decrease in operating expenses were as follows:

- General and administrative expenses decreased \$6,353 during the three months ended September 30, 2021, as compared
  to the corresponding period of fiscal 2020, primarily due to a reduction of legal fees and rental and lease expenses
  incurred.
- Compensation expense increased \$(2,393) during the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020, primarily due additional staff required to manage the Company's expanded operations, including the acquisitions of certain Maine operations since the comparable period and CWG in May 2021. Additionally, compensation expense in the comparable period of 2020 was reduced as a result of reorganization efforts, including a suspension of operations at Form Factory and temporary staff reductions undertaken in response to the COVID-19 pandemic.
- Equity-based compensation expense decreased \$6,277 during the three months ended September 30, 2021, as compared to the corresponding period of fiscal 2020, primarily due to benefits associated with the reorganization efforts undertaken

in the previous period, resulting in the acceleration of restricted share vesting for certain employees and previously issued awards becoming fully vested and cancelled in the prior periods.

- Impairments, net for the three months ended September 30, 2021 increased \$2,339 due to the write-off of capital assets
  at the Sewell, New Jersey locations resulting from damage by Hurricane Ida. The loss was recognized net of expected
  insurance proceeds.
- During the three months ended September 30, 2020, the Company determined certain businesses and assets met the
  held-for-sale criteria. In accordance with ASC 360-10, Property, Plant and Equipment, the assessed disposal groups for
  such assets held-for-sale were written down to fair value less costs to sell, resulting in the recognition of write down
  charges. No such write-down was required for the three months ended September 30, 2021.
- During the three months ended September 30, 2020, the Company recorded a charge of \$14,150 due to the recognition
  of litigation accruals for various matters. No such provision was required for the three months ended September 30,
  2021.
- Depreciation and amortization expenses increased \$(2,648) during the three months ended September 30, 2021, compared to the corresponding period of fiscal 2020, primarily due to an acceleration of the amortization of certain intangible assets as a result of a reduction in the expected useful lives of such assets.

Total operating expenses for the nine months ended September 30, 2021 were \$79,745, a decrease of \$284,092 or 78% from the corresponding period of fiscal 2020. The primary drivers of the decrease in operating expenses were as follows:

- General and administrative expenses decreased \$17,170 during the six months ended September 30, 2021, as compared
  to the corresponding period of fiscal 2020, primarily due to a reduction of legal fees and rental and lease expenses
  incurred.
- Compensation expense increased slightly by \$(1,496) for the nine months ended September 30, 2021, as compared to the corresponding period of fiscal 2020 Staff increases due to additional staff required to manage the Company's expanded operations were somewhat offset by reorganization efforts undertaken in previous periods.
- Equity-based compensation expense decreased \$48,178 during the nine months ended September 30, 2021, as compared
  to the corresponding period of fiscal 2020, primarily due to benefits associated with the reorganization efforts undertaken
  in the previous period, resulting in the acceleration of restricted share vesting for certain employees and previously
  issued awards becoming fully vested and cancelled in the prior periods.
- Impairments, net for the nine months ended September 30, 2021 included a \$2,339 write-off of the capital assets at the Sewell, New Jersey locations resulting from damage by Hurricane Ida. The loss was recognized net of expected insurance proceeds. Impairment expenses, net of \$187,775 for the nine months ended September 30, 2020 included impairment charges related to interim intangible and goodwill impairment testing undertaken in the prior period due to the triggering event caused by the COVID-19 pandemic, as further discussed in Note 4 in the unaudited condensed consolidated financial statements.
- The loss on notes receivable of \$1,726 for the nine months ended September 30, 2021 is due to the determination that the payment for certain notes receivables was doubtful based on the most recent information available to the Company. The loss on notes receivable for the comparable period in 2020 of \$8,161 was due to the write-off of a notes receivable that the Company determined was no longer collectible.
- During the nine months ended September 30, 2020, the Company determined certain businesses and assets met the held-for-sale criteria. In accordance with ASC 360-10, *Property, Plant and Equipment*, the assessed disposal groups for such assets held-for-sale were written down to fair value less costs to sell, resulting in the recognition of write down charges of \$11,003. No such write-down was required for the nine months ended September 30, 2021. During the nine months ended September 30, 2021, the Company determined that the fair value less costs to sell of its Acreage Florida disposal group increased \$8,616 in excess of its value previously written down value. Accordingly, the Company recognized a

recovery of assets held-for-sale related to its Acreage Florida disposal group related to the previously recognized write-downs. Refer to Notes 3 and 17 in the unaudited condensed consolidated financial statements for further discussion.

- During the nine months ended September 30, 2020, the Company recorded a charge of \$14,150 due to the recognition
  of litigation accruals for various matters. No such provision was required for the nine months ended September 30,
  2021.
- Depreciation and amortization expenses increased during the nine months ended September 30, 2021, compared to the
  corresponding period of fiscal 2020, primarily due to an acceleration of the amortization of certain intangible assets as
  a result of a reduction in the expected useful lives of such assets.

## Total other (loss) income

Other (loss) income			Better/(V	Vorse)			Better/(V	Vorse)
in thousands	Three Months Ended September 30,		2021 vs.	2020	- ,	oths Ended	2021 vs. 2020	
	2021	2020	\$	%	2021	2020	\$	%
(Loss) income from investments, net	\$ 489	\$ (433)	\$ 922	n/m	\$ (777)	\$ (195)	\$ (582)	(298)%
Interest income from loans receivable	1,067	1,606	(539)	(34)%	4,125	5,083	(958)	(19)%
Interest expense	(3,620)	(6,147)	2,527	41 %	(14,072)	(11,106)	(2,966)	(27)
Other income (loss), net	81	(656)	737	n/m	7,825	(853)	8,678	n/m
Total other income (loss)	\$ (1,983)	\$ (5,630)	\$ 3,647	65 %	\$ (2,899)	\$ (7,071)	\$ 4,172	59
n/m - Not Meaningful								

Total other loss for the three months ended September 30, 2021 was \$(1,983), an decrease of \$3,647 from the corresponding period of fiscal 2020. The primary drivers of the increase in other loss were as follows:

- Income from investments, net of \$489 for the three months ended September 30, 2021 was primarily due to gains in the fair market value of investments in equity of entities where the Company does not have significant influence or control.
- Interest income from loans receivable of \$1,067 for the three months ended September 30, 2021 has declined \$(539) from the corresponding period of fiscal 2020 due to a reduction in the value of loans receivable outstanding.
- Interest expense, net of \$(3,620) decreased \$2,527 during the three months ended September 30, 2021, compared to the
  corresponding period of fiscal 2020, due to the Company's decreased level of net debt coupled with reduced rates of
  interest on the Company's debt obligations.

Total other income (loss) for the nine months ended September 30, 2021 was \$(2,899), a decrease of \$4,172 from the other income (loss) recognized in the corresponding period of fiscal 2020. The primary drivers of the decrease in other income (loss) for the nine months ended September 30, 2021 were as follows:

- Loss from investments, net of \$(777) for the nine months ended September 30, 2021 was primarily due to declines in
  the fair market value of investments in equity of entities where the Company does not have significant influence or
  control.
- Interest income from loans receivable of \$4,125 for the nine months ended September 30, 2021 has declined \$(958) from the corresponding period of fiscal 2020 due to a reduction in the value of loans receivable outstanding.
- Interest expense, net of \$(14,072) increased \$(2,966) during the nine months ended September 30, 2021, compared to the corresponding period of fiscal 2020, due to the Company's increased debt financing transactions primarily undertaken subsequent to June 30, 2020 and somewhat offset with reduced rates of interest on the Company's debt obligations for the nine months ended September 30, 2021.

• Other income (loss), net for the nine months ended September 30, 2021 of \$7,825 included a gain on the sale of Acreage Florida of \$11,682, partially offset by i) a loss on the subsequent sale of notes receivable received as consideration from the buyer of Acreage Florida of approximately \$2,000, and ii)iii) a loss of \$1,644 on the disposal of capital assets.

#### Net loss

Net loss	Better/(Worse)						Better/(Worse)		
in thousands	Three Months Ended September 30, 20		2021 v	2021 2020			Months Ended 2021 vs.		
	2021	2020	\$	%	2021	2020	\$	%	
Net loss	\$(14,058)	\$ (48,036)	\$ 33,978	71 %	\$ (26,004)	\$(314,635)	\$288,631	92 %	
Less: net loss attributable to non- controlling interests	(1,761)	(7,488)	5,727	76 %	(3,347)	(64,941)	61,594	95 %	
Net loss attributable to Acreage Holdings. Inc.	\$(12,297)	\$ (40,548)	\$ 28,251	70 %	\$ (22,657)	\$(249,694)	\$227,037	91 %	

The decreases in net loss are driven by the factors discussed above.

### **Non-GAAP Information**

This statement includes Adjusted EBITDA, which is a non-GAAP performance measure that we use to supplement our results presented in accordance with U.S. GAAP. The Company uses Adjusted EBITDA to evaluate its actual operating performance and for planning and forecasting future periods. The Company believes that the adjusted results presented provide relevant and useful information for investors because they clarify the Company's actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since these measures are not calculated in accordance with U.S. GAAP, they should not be considered in isolation of, or as a substitute for, net loss or our other reported results of operations as reported under U.S. GAAP as indicators of our performance, and they may not be comparable to similarly named measures from other companies.

The Company defines Adjusted EBITDA as net income before interest, income taxes and, depreciation and amortization and excluding the following: (i) income from investments, net (the majority of the Company's investment income relates to remeasurement to fair value of previously-held interests in connection with our roll-up of affiliates, and the Company expects income from investments to be a non-recurring item as its legacy investment holdings diminish), (ii) equity-based compensation expense, (iii) non-cash impairment losses, (iv) transaction costs and (v) other non-recurring expenses (other expenses and income not expected to recur).

Adjusted EBITDA	Better/(Worse)	Better/(Worse)

in thousands	Three Months Ended September 30,		2021 vs. 2020			nths Ended nber 30,	2021 vs. 2020	
	2021	2020	\$	%	2021	2020	\$	%
Net loss (U.S. GAAP)	\$(14,058)	\$(48,036)			\$(26,004)	\$(314,635)		
Income tax expense (benefit)	5,579	3,826			11,661	(21,633)		
Interest (income) expense, net	2,553	4,541			9,947	6,023		
Depreciation and amortization	4,590	1,396			11,384	4,888		
EBITDA (non-GAAP)	\$ (1,336)	\$(38,273)	\$36,937	97 %	\$ 6,988	\$(325,357)	\$332,345	n/m
Adjusting items:								
(Income) loss from investments, net	(489)	433			777	195		
Impairments, net	_	_			818	187,775		
Loss on Sewell facility	2,339	_			2,339	_		
Loss on notes receivable	_	_			1,726	8,161		
Write down (recovery) of assets held- for-sale	_	2,893			(8,616)	11,003		
Equity-based compensation expense	4,168	10,445			17,191	65,370		
Legal settlements, net	_	14,150			322	14,150		
Gain on business divestiture	(109)	_			(11,791)	_		
Transaction costs	_	3,114			_	3,114		
Other non-recurring expenses	1,924	355			6,425	9,605		
Adjusted EBITDA (non-GAAP)	\$ 6,497	\$ (6,883)	\$13,380	n/m	\$ 16,179	\$ (25,984)	\$ 42,163	n/m
n/m - Not Meaningful								

The increases in adjusted EBITDA are driven by the factors discussed above.

## LIQUIDITY AND CAPITAL RESOURCES

## Liquidity

## Sources and uses of cash

The Company's primary uses of capital include operating expenses, capital expenditures and the servicing of outstanding debt. The Company's primary sources of capital include funds generated by cannabis sales as well as financing activities. Through September 30, 2021, the Company had primarily used private financing as a source of liquidity for short-term working capital needs and general corporate purposes.

In March 2021, the Company extended the maturity date related to \$21,000 of the \$22,000 aggregate amount of the loan transaction to June 30, 2021, as described in Note 10 to the unaudited condensed consolidated financial statements.

In June 2021, the Company repaid the 3.55% credit facility of \$21,000 and the 3.55% credit facility collateral (related party) of \$22,000. Certain of the cash proceeds from the sale of Acreage Florida, including the proceeds from the sale of the notes received from the buyer of Acreage Florida as consideration, and the Company's restricted cash were utilized to repay these debt obligations.

As of September 30, 2021, the Company had cash of \$27,868 (not including approximately \$1,098 of restricted cash and approximately \$518 of cash held for sale and included in current assets held for sale). The Company's ability to fund its operations, capital expenditures, acquisitions, and other obligations depends on its future operating performance and ability to obtain financing, which are subject to prevailing economic conditions, as well as financial, business and other factors, some of which are beyond the Company's control.

The Company expects that its cash on hand and cash flows from operations, along with its ability to obtain private and/or public financing, will be adequate to support the capital needs of the existing operations as well as expansion plans for the next 12 months. While the Company's liquidity risk has increased since its RTO transaction as a result of the Company's rapid growth and continued expansion, which resulted in negative operating cash flow for the year ended December 31, 2020, the Company believes it has alleviated the risk. Please refer to the disclosures under "Basis of presentation and going concern" in Note 2 to the unaudited condensed consolidated financial statements.

## Cash flows

Cash and cash equivalents, restricted cash, and cash held for sale were \$29,484 as of September 30, 2021, an increase of \$38,975 from September 30, 2020. The following table summarizes the change in cash, cash equivalents, restricted cash, and cash held for sale for the nine months ended September 30, 2021 and 2020.

Cash flows						Better/(V	Worse)	
in thousands	Nin	e Months End	ded Se	eptember 30,	2021 vs. 2020			
		2021		2020		\$	%	
Net cash used in operating activities	\$	(18,312)	\$	(44,208)	\$	25,896	59 %	
Net cash provided by (used in) investing activities		34,152		(63,681)		97,833	n/m	
Net cash (used in) provided by financing activities		(40,995)		149,748		(190,743)	n/m	
Net (decrease) increase in cash, cash equivalents, restricted cash, and cash held for sale	\$	(25,155)	\$	41,859	\$	(67,014)	n/m	
n/m - Not Meaningful								

## Net cash used in operating activities

For the nine months ended September 30, 2021, the Company used \$18,312 of net cash in operating activities. This represented a reduction of \$25,896 when compared to the corresponding period of fiscal 2020. Excluding non-cash items such as impairments, equity based compensation, write-offs, gains and losses on disposals and depreciation and amortization in the net operating income (loss), this improved operating income was a result of revenue increases exceeding increases in costs of goods sold and a decrease in non-cash expenditures. Additionally, for both the nine months ended September 30, 2021 and 2020, cash used in operating activity included cash used to fund increases in working capital due to the expanded operations.

## Net cash (used in) provided by investing activities

For the nine months ended September 30, 2021, the Company provided \$34,152 of net cash through investing activities. This represented an improvement of \$97,833 when compared to the corresponding period of fiscal 2020. Cash provided by investing activities for the nine months ended September 30, 2021, was primarily driven by \$27,535 spent on capital expenditures to build out the Company's owned operations but this was more than offset by (i) \$9,307 collected from entities, net of advances, and (ii) \$50,407 net proceeds from the sale of assets..

Cash used in investing activities during the nine months ended September 30, 2020, was primarily driven by (i) \$7,904 spent on capital expenditures to build out the Company's owned operations, (ii) \$13,958 advanced to entities, net of collections, and (iii) \$9,983 on business acquisitions.

# Net cash (used in) provided by financing activities

For the nine months ended September 30, 2021, the Company used \$40,995 of net cash in financing activities. This represented a decrease of \$115,928 when compared to the corresponding period of fiscal 2020. Cash used in financing activities during the nine months ended September 30, 2021 was primarily driven by the repayment of debt of \$46,321, partially offset by \$6,301 related to financing proceeds.

Cash provided by financing activities during the nine months ended September 30, 2020 was primarily driven by (i) \$134,000 raised through debt financing, (ii) \$27,887 through equity transactions, (iii) \$22,000 collateral received from prior financing arrangements and (iv) offset by \$30,822 repayment of debt.

#### **Capital Resources**

### Capital structure and debt

The Company's debt outstanding as of September 30, 2021 was as follows:

Debt balances	Sep	otember 30, 2021
Seller's notes	\$	2,581
Financing liability (related party)		15,253
Finance lease liabilities		5,228
7.5% Loan due 2023 (related party)		32,328
6.1% Secured debenture due 2030 (related party)		45,936
Hempco Foros promissory note		_
Senior secured term loan facility		23,482
Construction financing loan		11,255
Canwell promissory note		6,500
Total debt	\$	142,563
Less: current portion of debt		16,377
Total long-term debt	\$	126,186